{
  "main_header": {
    "sid": 905552,
    "name": "Anuh Pharma",
    "stock_name": "Anuh Pharma",
    "full_name": "Anuh Pharma Ltd",
    "name_url": "stocks-analysis/anuh-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "172.50",
    "chg": 4.95,
    "chgp": "2.95%",
    "dir": 1,
    "prev_price": "167.55",
    "mcapval": "864.43 Cr",
    "mcap": "Micro Cap",
    "scripcode": 506260,
    "symbol": "ANUHPHR",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE489G01022",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "01:24 AM",
    "bse_nse_vol": "13.87 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/anuh-pharma-905552-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Anuh Pharma Faces Continued Volatility Amid Declining Financial Performance and Market Confidence",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-hits-52-week-low-amid-declining-profit-and-bearish-trends-1425854",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/AnuhPharma_priceRelatedfactors_684753.png",
        "date": "2025-03-18 09:54:45",
        "description": "Anuh Pharma has faced significant volatility, reaching a new 52-week low and continuing a trend of underperformance in the Pharmaceuticals & Drugs sector. The company has seen a substantial decline over the past year, with disappointing financial metrics and a lack of investment interest from domestic mutual funds."
      },
      {
        "title": "Anuh Pharma Hits 52-Week Low Amid Broader Market Gains and Ongoing Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-hits-52-week-low-amid-continued-stock-decline-and-poor-performance-4-1425840",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/AnuhPharma_priceRelatedfactors_684750.png",
        "date": "2025-03-18 09:54:41",
        "description": "Anuh Pharma has reached a new 52-week low after five consecutive days of price declines, despite a slight recovery today. The company's performance over the past year has been poor, with a significant drop compared to the broader market. Financial metrics indicate low debt and moderate return on equity, but profitability has declined."
      },
      {
        "title": "Anuh Pharma Hits 52-Week Low Amidst Ongoing Financial Struggles and Sector Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-hits-52-week-low-amid-ongoing-stock-decline-and-market-underperformance-1425789",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/AnuhPharma_priceRelatedfactors_684751.png",
        "date": "2025-03-18 09:54:40",
        "description": "Anuh Pharma has reached a new 52-week low, reflecting a challenging year with a 31.97% performance decline. The company has underperformed its sector and is trading below key moving averages. Recent quarterly results indicate significant drops in profit, while domestic mutual funds show no investment interest."
      },
      {
        "title": "Anuh Pharma Hits 52-Week Low Amid Broader Market Rally and Small-Cap Gains",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-hits-52-week-low-amid-continued-decline-and-poor-performance-metrics-1425905",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/AnuhPharma_priceRelatedfactors_684752.png",
        "date": "2025-03-18 09:54:40",
        "description": "Anuh Pharma has reached a new 52-week low, reflecting a significant decline in performance compared to its sector. Despite a broader market rally, the company has struggled over the past year, with disappointing sales growth and a recent drop in profitability, although it maintains a low debt-to-equity ratio."
      },
      {
        "title": "Anuh Pharma Faces Significant Volatility Amid Weak Growth Prospects and Market Concerns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-hits-52-week-low-amid-continued-stock-decline-and-poor-performance-1405815",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/AnuhPharma_priceRelatedfactors_681985.png",
        "date": "2025-03-17 15:06:53",
        "description": "Anuh Pharma has faced notable volatility, reaching a new 52-week low amid a downward trend. The company's long-term growth prospects appear weak, with disappointing recent financial results. Technical indicators suggest a bearish trend, and the stock has significantly underperformed the broader market over the past year."
      },
      {
        "title": "Anuh Pharma Adjusts Valuation Amidst Competitive Pharmaceutical Landscape Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharmas-valuation-grade-downgraded-from-very-attractive-to-attractive-2-1259205",
        "imagepath": "",
        "date": "2025-03-10 08:00:47",
        "description": "Anuh Pharma, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 165.85, reflecting a slight increase from the previous close of 162.85. Over the past year, Anuh Pharma has experienced a stock return of -27.27%, contrasting with a modest gain of 0.29% in the Sensex.\n\nKey financial metrics for Anuh Pharma include a PE ratio of 16.54 and an EV to EBITDA ratio of 12.91, which positions it competitively within its industry. The company also boasts a return on capital employed (ROCE) of 23.53% and a return on equity (ROE) of 16.58%, indicating effective management of its resources.\n\nIn comparison to its peers, Anuh Pharma's valuation metrics reveal a more attractive position relative to companies like Shree Ganesh Remedies and Fermenta Biotec, which are categorized as expensive. Meanwhile, firms such as Kopran and NGL Fine ..."
      },
      {
        "title": "Anuh Pharma Faces Financial Challenges Amid Declining Performance and Market Sentiment",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/anuh-pharma-reports-significant-profit-declines-amid-bearish-stock-trend-1200821",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/AnuhPharma_mojoScore_578921.png",
        "date": "2025-03-05 08:09:47",
        "description": "Anuh Pharma, a microcap in the Pharmaceuticals & Drugs sector, has recently experienced an evaluation adjustment amid financial challenges, particularly in Q3 FY24-25. Key metrics, including profit before and after tax, have shown declines, contributing to a bearish market sentiment and limited interest from domestic mutual funds."
      },
      {
        "title": "Anuh Pharma Hits New Low Amid Ongoing Downward Trend and Sector Comparison",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-hits-new-52-week-low-as-stock-declines-4-55-over-three-days-1173189",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/3/AnuhPharma_priceRelatedfactors_562622.png",
        "date": "2025-03-03 10:36:39",
        "description": "Anuh Pharma has reached a new 52-week low, continuing a downward trend with a 4.55% decline over three days. Despite slightly outperforming its sector today, the stock has fallen 30.63% over the past year, significantly underperforming compared to the Sensex. Technical indicators show a persistent bearish trend."
      },
      {
        "title": "Anuh Pharma Hits New Low Amid Ongoing Underperformance in Pharmaceutical Sector",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-hits-52-week-low-stock-declines-24-62-over-past-year-1140174",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/2/AnuhPharma_priceRelatedfactors_547825.png",
        "date": "2025-02-28 09:38:50",
        "description": "Anuh Pharma has reached a new 52-week low, continuing a downward trend with a 1.96% decline over the past two days. The stock has underperformed its sector and is trading below multiple moving averages, reflecting ongoing challenges in the market and a 24.62% decrease over the past year."
      }
    ],
    "total": 3098,
    "sid": "905552",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/anuh-pharma-905552"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Apr-2025",
      "details": "Compliance Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended 31st March 2025 received from Bigshare Services Private Limited Registrar and Share Transfer Agent (RTA) of our company. We request you to kindly take the same on record.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "26-Mar-2025",
      "details": "Intimation regarding the Closure of Trading Window for dealing in securities of the company shall remain closed from Tuesday 01st April 2025 till the expiry of 48 hours after the declaration of Audited Financial Results for the year ended 31st March 2025.",
      "source": "BSE"
    },
    {
      "caption": "Non-Applicability Of Statement Of Deviation(S) And Variation(S) Under Regulation 32(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "13-Feb-2025",
      "details": "Non-applicability of Statement of Deviation(s) and Variation(s) under Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has declared <strong>50%</strong> dividend, ex-date: 16 Aug 24",
          "dt": "2024-08-16",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has announced <strong>5:10</strong> stock split, ex-date: 31 Jul 06",
          "dt": "2006-07-31",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 18 Sep 20",
          "dt": "2020-09-18",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Anuh Pharma Faces Continued Volatility Amid Declining Financial Performance and Market Confidence

2025-03-18 09:54:45

Anuh Pharma has faced significant volatility, reaching a new 52-week low and continuing a trend of underperformance in the Pharmaceuticals & Drugs sector. The company has seen a substantial decline over the past year, with disappointing financial metrics and a lack of investment interest from domestic mutual funds.

Read More

Anuh Pharma Hits 52-Week Low Amid Broader Market Gains and Ongoing Challenges

2025-03-18 09:54:41

Anuh Pharma has reached a new 52-week low after five consecutive days of price declines, despite a slight recovery today. The company's performance over the past year has been poor, with a significant drop compared to the broader market. Financial metrics indicate low debt and moderate return on equity, but profitability has declined.

Read More

Anuh Pharma Hits 52-Week Low Amidst Ongoing Financial Struggles and Sector Underperformance

2025-03-18 09:54:40

Anuh Pharma has reached a new 52-week low, reflecting a challenging year with a 31.97% performance decline. The company has underperformed its sector and is trading below key moving averages. Recent quarterly results indicate significant drops in profit, while domestic mutual funds show no investment interest.

Read More

Anuh Pharma Hits 52-Week Low Amid Broader Market Rally and Small-Cap Gains

2025-03-18 09:54:40

Anuh Pharma has reached a new 52-week low, reflecting a significant decline in performance compared to its sector. Despite a broader market rally, the company has struggled over the past year, with disappointing sales growth and a recent drop in profitability, although it maintains a low debt-to-equity ratio.

Read More

Anuh Pharma Faces Significant Volatility Amid Weak Growth Prospects and Market Concerns

2025-03-17 15:06:53

Anuh Pharma has faced notable volatility, reaching a new 52-week low amid a downward trend. The company's long-term growth prospects appear weak, with disappointing recent financial results. Technical indicators suggest a bearish trend, and the stock has significantly underperformed the broader market over the past year.

Read More

Anuh Pharma Adjusts Valuation Amidst Competitive Pharmaceutical Landscape Dynamics

2025-03-10 08:00:47

Anuh Pharma, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 165.85, reflecting a slight increase from the previous close of 162.85. Over the past year, Anuh Pharma has experienced a stock return of -27.27%, contrasting with a modest gain of 0.29% in the Sensex. Key financial metrics for Anuh Pharma include a PE ratio of 16.54 and an EV to EBITDA ratio of 12.91, which positions it competitively within its industry. The company also boasts a return on capital employed (ROCE) of 23.53% and a return on equity (ROE) of 16.58%, indicating effective management of its resources. In comparison to its peers, Anuh Pharma's valuation metrics reveal a more attractive position relative to companies like Shree Ganesh Remedies and Fermenta Biotec, which are categorized as expensive. Meanwhile, firms such as Kopran and NGL Fine ...

Read More

Anuh Pharma Faces Financial Challenges Amid Declining Performance and Market Sentiment

2025-03-05 08:09:47

Anuh Pharma, a microcap in the Pharmaceuticals & Drugs sector, has recently experienced an evaluation adjustment amid financial challenges, particularly in Q3 FY24-25. Key metrics, including profit before and after tax, have shown declines, contributing to a bearish market sentiment and limited interest from domestic mutual funds.

Read More

Anuh Pharma Hits New Low Amid Ongoing Downward Trend and Sector Comparison

2025-03-03 10:36:39

Anuh Pharma has reached a new 52-week low, continuing a downward trend with a 4.55% decline over three days. Despite slightly outperforming its sector today, the stock has fallen 30.63% over the past year, significantly underperforming compared to the Sensex. Technical indicators show a persistent bearish trend.

Read More

Anuh Pharma Hits New Low Amid Ongoing Underperformance in Pharmaceutical Sector

2025-02-28 09:38:50

Anuh Pharma has reached a new 52-week low, continuing a downward trend with a 1.96% decline over the past two days. The stock has underperformed its sector and is trading below multiple moving averages, reflecting ongoing challenges in the market and a 24.62% decrease over the past year.

Read More

View All News